Navigation Links
Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Date:5/4/2012

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com. The webcast can also be accessed at the following URL: http://www.veracast.com/webcasts/baml/healthcare2012/id16635640.cfm

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com. CONTACTS: Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Photo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016   Purdue ... entered into an agreement with Egalet Corporation and ... claims. As part of the agreement the companies ... will enable all three companies to develop and ... "This agreement reflects the commitment of ...
(Date:5/20/2016)... 20, 2016 ReportsnReports.com adds ... Medical Devices of its online business intelligence library. ... the current state of the Titrator industry. The ... like definitions, classifications, Specifications, applications and industry chain ... like Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost ...
(Date:5/20/2016)... LONDON , May 20, 2016 ... for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant ... Emerging Biological Drugs - This New Study Reveals ... Stay Ahead ,What is the ... get the latest technological and commercial analysis. Staying ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... ... Edward D. Buckingham, M.D . is excited announce that he has been ... out by the National Consumer Advisory Board to honor excellence in medicine. Only doctors ... award. , The National Consumer Advisory Board (NCAB) is a private organization created to ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical ... representatives from the Japan PMDA, US FDA, industry and academia at the ... help format data from clinical trials so that it can be shared and ...
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, ... host medical device summit on September 15 and 16, 2016 in San Diego, ... former FDA office bearers will be one of the largest gatherings of medical device ...
(Date:5/23/2016)... ... May 23, 2016 , ... In Pursuit of Balance (IPOB) co-founders Jasmine Hirsch ... operations at the end of 2016. , “We created IPOB to change the ... we look back on what we have achieved, we’re gratified by the response of ...
(Date:5/23/2016)... ... 2016 , ... Bio-Optronics, Inc. is delighted to announce recent ... recent and anticipated growth. , Max Elbaz was appointed as Vice President, Sales ... Max joined the Bio-Optronics team in March. His areas of expertise include international ...
Breaking Medicine News(10 mins):